Comments by "Deborah Freedman" (@deborahfreedman333) on "Potential breakthrough: New treatment for Alzheimer's" video.

  1. This is the first study, that shows some effectiveness. Others showed it did nothing significant. But, one of the drug partners published a paper, showing how much care cost it could save, and now this MAb is in the news.
    2
  2. This is not the first MAb (monoclonal antibody) against amyloid-beta. But, aducanumab, bapineuzumab, gantenerumab, solanezumab, and lecanemab did not show any significant effect, in numerous previous studies. I'd like to see these positive lecanemab results be duplicated, since previous studies, on the same MAb showed it next to useless. Although the original treatment cost, of $56K/year, is now halved, because of recent legislation, that's still a lot of money.
    2
  3. @Zepparella Dakunish You keep posting the same BS. Mastinib is a tyrosine-kinase inhibitor, not a monoclonal antibody.
    1
  4. And previous studies, on the same MAb, have shown it doesn't even significantly slow progression. I think all this "good news" is due to Eisai promoting a cost/benefit analysis, claiming it can keep people out of long term care, and save money. But, that is based upon the proposal that it works, when other studies show it does not.
    1